Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Current Trends Reye Syndrome Surveillance -- United States, 1987 and 1988

For the 1987 and 1988 surveillance years, 36 and 20 cases,* respectively, of Reye syndrome (RS)** were reported to the National Reye Syndrome Surveillance System. These years have the lowest number of cases reported since continuous national surveillance was established in December 1976 (Table 1). For both years, approximately 80% of reported patients had an antecedent illness within 3 weeks before onset of vomiting or neurologic symptoms. Eighteen RS patients in 1987 and nine in 1988 had respiratory illnesses; seven and four had varicella; three and two had diarrhea without respiratory symptoms. In both years, approximately 50% of cases occurred in January, February, and March--the peak months for respiratory viral infections, including varicella and influenza (type A(H1N1) in 1987 and type A(H3N2) in 1988).

In 1987, 17 (47%) of the 36 reported RS patients and, in 1988, 16 (80%) of the 20 patients were female; 33 (92%) and 19 (95%), respectively, were white, two (6%) and one (5%) were black, and one patient (3%) in 1987 was Asian. Seventeen patients each year were greater than or equal to 5 years old, representing a 75% decline in the number of cases in this age group from 1986. Nineteen reported patients in 1987 and three in 1988 were less than 5 years old, representing a 42% and a 91% decline, respectively, in this age group from 1986.

Approximately 75% of patients in both 1987 and 1988 were admitted to hospitals in precomatose stages of RS--stages 0, 1, or 2.*** In each year, stage 2 was the classification for the largest number of patients upon admission (47% and 55%, respectively), followed by stage 1 for 1987 (31%) and stages 0, 1, and 3 (10% each) for 1988. In 1987, the most severe phases of illness after hospitalization were stage 1 (25%), stage 2 (8%), stage 3 (8%), stage 4 (11%), and stage 5 (30%). Eleven percent of patients received treatment that precluded classification (i.e., they had received anesthetic or paralyzing agents in their treatment); the most severe stage was not reported for 7%. In 1988, 25% reached stage 1 only; 5% reached stage 2, 20% reached stage 3, 20% reached stage 5, and 30% received treatment that precluded classification.

The case-fatality rates for these 2 years were 29% and 30%, respectively, based on patients for whom short-term outcome was reported (35 (97%) of the 36 patients in 1987 and 17 (85%) of the 20 patients in 1988). Reported by: Epidemiology Office, Div of Viral and Rickettsial Diseases, Center for Infectious Diseases, CDC.

Editorial Note

Editorial Note: The annual number of RS cases reported to CDC has decreased steadily since 1980. Major studies on RS and medications (1-3) have confirmed prior reports (4-6) of an association between ingestion of aspirin during antecedent viral illness and subsequent development of RS. The decline in the number of RS cases since late 1980 coincides with the increased publicity about this association and with the decrease in the frequency and/or dose of aspirin-containing medication used in treating children with influenza-like illness or varicella (7,8). In addition, since 1986, labels of all aspirin-containing medications have been required to provide a warning about the risk of RS in association with aspirin use in children with influenza-like illness and varicella.

Before diagnosing RS, physicians should rule out any of the approximately 20 metabolic disorders that may mimic RS, particularly in infants and small children (2,9-11). Because 40%-65% of reported RS patients since 1985 have been greater than or equal to 10 years of age, health-care providers and public health agencies also should advise older children and their parents about warnings concerning aspirin use.

Interest in reporting RS may wane as the number of cases decreases in the United States. Health-care providers and public health agencies are urged to continue reporting to the National Reye Syndrome Surveillance System to assure adequate epidemiologic monitoring of this illness. References

  1. Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study on Reye's syndrome and medications: report of the pilot phase. N Engl J Med 1985;313:849-57. 2.Hurwitz ES, Barrett MJ, Bregman D, et al. Public Health Service study of Reye's syndrome and medications: report of the main study. JAMA 1987;257:1905-11,3366. 3.Pinsky PF, Hurwitz ES, Schonberger LB, Gunn WJ. Reye's syndrome and aspirin: evidence for a dose-response effect. JAMA 1988;260:657-61. 4.Starko KM, Ray CG, Dominguez LB, Stromberg WL, Woodall DF. Reye's syndrome and salicylate use. Pediatrics 1980;66:859-64. 5.Waldman RJ, Hall WN, McGee H, Van Amburg G. Aspirin as a risk factor in Reye's syndrome. JAMA 1982;247:3089-94. 6.Halpin TJ, Holtzhauer FJ, Campbell RJ, et al. Reye's syndrome and medication use. JAMA 1982;248:687-91. 7.Remington PL, Rowley D, McGee H, Hall WN, Monto AS. Decreasing trends in Reye syndrome and aspirin use in Michigan, 1979 to 1984. Pediatrics 1986;77:93-8. 8.Barret MJ, Hurwitz ES, Schonberger LB, Rogers MF. Changing epidemiology of Reye syndrome in the United States. Pediatrics 1986;77:598-602. 9.Hurwitz ES. The changing epidemiology of Reye's syndrome in the United States: further evidence for a public health success (Editorial). JAMA 1988;260:3178-80. 10.Greene CL, Blitzer MG, Shapira E. Inborn errors of metabolism and Reye syndrome: differential diagnosis. J Pediatr 1988;113:156-9. 11.Rowe PC, Valle D, Brusilow SW. Inborn errors of metabolism in children referred with Reye's syndrome: a changing pattern. JAMA 1988;260:3167-70. *Reporting year begins December 1 of previous year. Data for 1988 are provisional. **According to CDC's case definition, the following conditions must be met to be considered an RS case: 1) acute, noninflammatory encephalopathy documented by alteration in the level of consciousness and either a) a record (if available) of cerebrospinal fluid containing less than or equal to 8 leukocytes per mm3 or b) histologic sections of the brain demonstrating cerebral edema without perivascular or meningeal inflammation; 2) hepatopathy documented either by biopsy or autopsy considered to be diagnostic of RS or by a threefold or greater rise in the levels of either serum aspartate aminotransferase, serum alanine aminotransferase, or serum ammonia; and 3) no more reasonable explanation for the cerebral or hepatic abnormalities. ***Clinical staging of encephalopathy in RS is based on the level of consciousness and corresponding physical signs. Stages 0-2 are precomatose, with the level of consciousness deteriorating progressively from stage 0 to stage 2. Stages 3-5 are characterized by coma, progressing from early (stage 3) to deep coma (stage 5).



Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to MMWR readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites. URL addresses listed in MMWR were current as of the date of publication.


All MMWR HTML versions of articles are electronic conversions from typeset documents. This conversion might result in character translation or format errors in the HTML version. Users are referred to the electronic PDF version (http://www.cdc.gov/mmwr) and/or the original MMWR paper copy for printable versions of official text, figures, and tables. An original paper copy of this issue can be obtained from the Superintendent of Documents, U.S. Government Printing Office (GPO), Washington, DC 20402-9371; telephone: (202) 512-1800. Contact GPO for current prices.

**Questions or messages regarding errors in formatting should be addressed to mmwrq@cdc.gov.

 
USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO
A-Z Index
  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
  27. #